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Abstract 
The very early onset of platinum hypersensitivity reaction in a dentist treated with 
external beam radiation and weekly carboplatin for a locally advanced squamous cell 
carcinoma of the skin raises the provocative issue of whether occupational exposure to 
platinum may have contributed to this most unusual clinical event. 
 
Introduction 
The platinum agents are currently among the most widely employed anti-neoplastic 
drugs with demonstrated major biological and clinical activity in multiple tumor types. 
While the individual agents (cisplatin, carboplatin, oxaliplatin) exhibit differing side 
effect profiles, they all share a most unfortunate risk for the development of 
hypersensitivity reactions. The signs and symptoms of these events can range from mild 
rash and diffuse erythroderma to serious anaphylactic reactions and death [1, 2]. 
One particularly highly characteristic feature of platinum allergic reactions is the 
observation that the initial clinical event (e.g. rash, dyspnea, hypotension) revealing 
hypersensitivity essentially always occurs following the delivery of multiple cycles (in most 
cases >6) of this specific class of drugs [1, 2]. In fact, it is far more common for an allergic 
reaction to carboplatin or cisplatin in an ovarian cancer patient to be encountered during 
second-line administration of the agent (following 5–6 prior courses given in the front-
line setting) than when one of the agents is infused as a component of front-line disease 
management [2]. 
It has been hypothesized that platinum hypersensitivity results from the stimulation of 
the immune system in susceptible individuals due to non-measurable concentrations of  
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metallic platinum contaminants (a known potent environmental allergen) during the 
drug manufacturing process [3–5]. However, since the actual quantity of systemic 
metallic platinum entering the body in this setting must be extremely small, repeated 
exposure is theorized to be necessary for the generation of an adequate immune response 
that will ultimately result in an allergic reaction. 
A recently encountered patient with metastatic squamous cell carcinoma of the skin 
and no known prior exposure to a platinum chemotherapeutic agent was treated with 
weekly carboplatin plus external radiation, and developed a very surprising but 
unequivocal allergic drug reaction (diffuse rash) following only the second cycle of the 
chemotherapy. This case is briefly presented, along with a potential explanation for this 
highly unusual clinical course. 
Case Report 
A 78-year-old retired dentist was found to have squamous cell carcinoma of the skin with the 
primary site being the left upper chest. Unfortunately, a month after primary surgical resection he was 
found to have developed a 2.6 cm metastatic lesion in the lower neck (left side). 
The mass was resected, but there was evidence of involvement in subcutaneous soft tissue and local 
lymph nodes. The tumor also extended to the deep soft tissue surgical margin. 
The patient had a past medical history of bladder cancer, treated both surgically and with local 
instillations of BCG. No chemotherapy was administered. The patient had no known allergies. 
Following discussions it was elected to treat the patient with external beam radiation to the neck 
along with weekly carboplatin (AUC 2), employed as a chemosensitization agent. The initial 
chemotherapy was given on day 1 of radiation, with the second cycle on day 8.  
The patient was noted to have a minimal diffuse rash on his legs prior to the administration of the 
third cycle of chemotherapy (day 15). A topical steroid was prescribed by a dermatologist. 
One day after this treatment cycle the patient noted marked worsening of the rash which spread 
diffusely but spared the oral cavity. There was no fever or evidence of organ dysfunction. Oral steroids 
were administered and the rash gradually resolved. Radiation was continued without further delivery of 
platinum chemotherapy.  
Discussion 
As many as 10–15% of patients receiving platinum for >6 treatment cycles may be 
anticipated to experience an allergic event directly related to this class of anti-neoplastic 
agents [2]. The observation of a clinical platinum-associated hypersensitivity reaction 
following the administration of the initial several cycles of this agent is extremely 
uncommon. For example, in one report of more than 200 women with gynecologic 
malignancies who were routinely treated with a platinum drug in both the primary and 
second-line settings there were no cases of platinum allergy noted prior to the sixth 
cumulative cycle containing this class of drugs [2]. 
Why might the individual presented in this case report who was not previously 
exposed to platinum-based chemotherapy have developed a platinum allergy so soon 
following initiation of carboplatin?  
Platinum hypersensitivity has been recognized for many years as being a serious 
occupational hazard for platinum miners [3–5]. While the current patient has no personal  
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history of direct prior exposure to platinum, he was a dentist and platinum is a commonly 
employed component present in dental restorations [6, 7]. 
Is it possible that this individual who was clearly susceptible to the development of a 
platinum hypersensitivity reaction may have been exposed (perhaps over a period of 
many years) to very low concentrations of platinum during his work [8]? If this theory is 
correct then following the initial weekly carboplatin infusion there was stimulation of 
immune system resulting in a clinical event after the next (second) exposure to the agent. 
It must be acknowledged that the preceding discussion is entirely speculative. 
However, it is consistent with both the historical facts and the clinical course of the 
allergic events in this patient.  
Further, this case suggests that patients who experience what appears to be the 
surprisingly early onset of platinum hypersensitivity should be questioned regarding 
possible prior occupational exposure (e.g. jeweler, platinum miner, dentist) that may have 
been at least partially responsible for this unexpected outcome. 
Nothing presented in this case report would argue that individual cancer patients with 
a known or suspected previous metallic platinum exposure should be denied the potential 
major clinical benefits associated with being given a platinum anti-neoplastic agent. 
However, knowledge of the patient’s history (as in the current case) may be helpful in 
explaining most surprising and unusual clinical events. 
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